Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals

Abstract

Nearly three fourths of survey respondents reported using RTU and POC products in conjunction with ADCs; however, the approach to including these products in ADCs varied based on the characteristics, policies, and preferences of the individual facility. Advantages of RTU and POC products identified by respondents included enhanced safety benefits, increased dispensing efficiency, cost avoidance due to reduced waste, and improved compliance with federal and state regulations.

Utilisation de lignes directrices dans le cadre de l’implantation de cabinets automatisés décentralisés en établissement de santé

“…Aucun article n'a été retrouvé en texte libre pour les termes Acudose-Rx, Omnicell, mais 24 sous Pyxis et 5 sous Pyxis Medstation. Parmi les articles recensés, notons quelques enquêtes décrivant la proportion d'utilisateurs 15 , quelques études descriptives examinant l'implantation et l'utilisation [16][17][18][19][20] , quelques études évaluant les conséquences de l'emploi des CAD sur les erreurs médicamenteuses 21,22 , quelques études économiques 23 , et une étude portant sur la perception de la fiabilité de CAD par le personnel soignant 24 . Depuis la publication d'un numéro spécial de Health Devices en 1996 sur les CAD, aucune autre publication n'a fait le point sur ce type de technologies et son rapport coût-bénéfice.…”

Aligning pharmacy and health-system objectives to eliminate central-line-associated bacteremias

“…products, and point-ofcare (POC) activated devices. 49 The premixed and frozen products eliminate the need for invasive product manipulation before dispensing and administration, thus reducing the risk for intraluminal or infusate contamination. POC activated parenteral products can be assembled in the pharmacy or on the unit by the nursing staff.…”

“…16,25,49 Challenges for pharmacists. External standards, guidelines, and payment policies are dictating professional practice to a greater degree than ever before.…”

“…Most pharmacy administrators (94.7%) have reported that their institution uses some form of RTU and POC activated parenteral products. 49 Despite the availability of these systems for many years, their effects on BSIs have not been evaluated. Using a 36-point scale quantifying the risks of an adverse drug event and of employee or patient infection, a Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems ranked RTU products most safe (36 points) and POC products the next safest (31 points) but did not report individual product scores.…”

“…A recent survey found that about one third of pharmacies assemble these doses, and approximately 50% activate the dose before it is available for administration. 49 Whether these activities are best performed in a cleanroom environment or in ambient air has not been studied. An optimum strategy would use one delivery system universally throughout a facility; however, this is not currently possible because each system has a limited product line and limited formulations for special populations (e.g., neonates, pediatrics).…”